| 0 |
INFLAMMATORY MYOFIBROBLASTIC TUMOUR |
1 |
0.0077 |
| 1 |
LUNG ADENOCARCINOMA STAGE IV |
1 |
0.0026 |
| 2 |
PELVIC FLUID COLLECTION |
1 |
0.0014 |
| 3 |
TUMOUR PSEUDOPROGRESSION |
1 |
0.0009 |
| 4 |
MYOCARDIAL INJURY |
1 |
0.0009 |
| 5 |
SMALL CELL LUNG CANCER |
1 |
0.0007 |
| 6 |
MYOCARDIAL NECROSIS MARKER INCREASED |
1 |
0.0006 |
| 7 |
ORGAN FAILURE |
1 |
0.0002 |
| 8 |
ANAPHYLACTOID REACTION |
1 |
0.0002 |
| 9 |
EAR DISORDER |
1 |
0.0002 |
| 10 |
INTRACRANIAL PRESSURE INCREASED |
1 |
0.0002 |
| 11 |
METASTASES TO LYMPH NODES |
1 |
0.0001 |
| 12 |
METASTASIS |
1 |
0.0001 |
| 13 |
TROPONIN INCREASED |
1 |
0.0001 |
| 14 |
HAEMOLYTIC ANAEMIA |
1 |
0.0001 |
| 15 |
SINUS BRADYCARDIA |
1 |
0.0001 |
| 16 |
BRAIN INJURY |
1 |
0.0001 |
| 17 |
MOUTH ULCERATION |
2 |
0.0001 |
| 18 |
SKIN INFECTION |
1 |
0.0001 |
| 19 |
MYOCARDITIS |
1 |
0.0001 |
| 20 |
SPLENOMEGALY |
1 |
0.0001 |
| 21 |
HYPERLIPIDAEMIA |
1 |
0.0001 |
| 22 |
ADRENAL INSUFFICIENCY |
1 |
0.0001 |
| 23 |
DRUG RESISTANCE |
2 |
0.0001 |
| 24 |
METASTASES TO CENTRAL NERVOUS SYSTEM |
1 |
0.0001 |
| 25 |
OEDEMA |
4 |
0.0001 |
| 26 |
CENTRAL NERVOUS SYSTEM LESION |
1 |
0.0001 |
| 27 |
SKIN HAEMORRHAGE |
1 |
0.0001 |
| 28 |
PNEUMOTHORAX |
1 |
0.0001 |
| 29 |
FACE OEDEMA |
1 |
0.0001 |
| 30 |
RASH PRURITIC |
3 |
0.0001 |
| 31 |
SKIN FISSURES |
1 |
0.0001 |
| 32 |
TASTE DISORDER |
1 |
0.0000 |
| 33 |
PERICARDIAL EFFUSION |
1 |
0.0000 |
| 34 |
NEURALGIA |
1 |
0.0000 |
| 35 |
AGEUSIA |
1 |
0.0000 |
| 36 |
MUCOSAL INFLAMMATION |
1 |
0.0000 |
| 37 |
ASPARTATE AMINOTRANSFERASE INCREASED |
2 |
0.0000 |
| 38 |
INTENTIONAL DOSE OMISSION |
1 |
0.0000 |
| 39 |
LIVER FUNCTION TEST ABNORMAL |
1 |
0.0000 |
| 40 |
DISEASE PROGRESSION |
4 |
0.0000 |
| 41 |
BLOOD POTASSIUM DECREASED |
1 |
0.0000 |
| 42 |
PLEURAL EFFUSION |
2 |
0.0000 |
| 43 |
ALANINE AMINOTRANSFERASE INCREASED |
2 |
0.0000 |
| 44 |
ADVERSE EVENT |
3 |
0.0000 |
| 45 |
EMOTIONAL DISORDER |
1 |
0.0000 |
| 46 |
DRUG-INDUCED LIVER INJURY |
1 |
0.0000 |
| 47 |
NEOPLASM PROGRESSION |
1 |
0.0000 |
| 48 |
CONSTIPATION |
6 |
0.0000 |
| 49 |
HEPATIC FUNCTION ABNORMAL |
1 |
0.0000 |
| 50 |
INTESTINAL OBSTRUCTION |
1 |
0.0000 |
| 51 |
SWELLING |
2 |
0.0000 |
| 52 |
ARRHYTHMIA |
1 |
0.0000 |
| 53 |
RASH |
9 |
0.0000 |
| 54 |
ATRIAL FIBRILLATION |
2 |
0.0000 |
| 55 |
PRURITUS |
7 |
0.0000 |
| 56 |
PRODUCT USE ISSUE |
3 |
0.0000 |
| 57 |
BLOOD CREATININE INCREASED |
1 |
0.0000 |
| 58 |
INFECTION |
2 |
0.0000 |
| 59 |
CONFUSIONAL STATE |
2 |
0.0000 |
| 60 |
SKIN EXFOLIATION |
1 |
0.0000 |
| 61 |
ADVERSE DRUG REACTION |
1 |
0.0000 |
| 62 |
DRUG INTOLERANCE |
1 |
0.0000 |
| 63 |
SYNCOPE |
1 |
0.0000 |
| 64 |
CHEST DISCOMFORT |
1 |
0.0000 |
| 65 |
MALIGNANT NEOPLASM PROGRESSION |
1 |
0.0000 |
| 66 |
HAEMORRHAGE |
1 |
0.0000 |
| 67 |
PLATELET COUNT DECREASED |
1 |
0.0000 |
| 68 |
DECREASED APPETITE |
2 |
0.0000 |
| 69 |
DRY SKIN |
1 |
0.0000 |
| 70 |
VISION BLURRED |
1 |
0.0000 |
| 71 |
HOSPITALISATION |
1 |
0.0000 |
| 72 |
FATIGUE |
5 |
0.0000 |
| 73 |
MYALGIA |
1 |
0.0000 |
| 74 |
ALOPECIA |
1 |
0.0000 |
| 75 |
HYPOTENSION |
1 |
0.0000 |
| 76 |
ABDOMINAL PAIN UPPER |
1 |
0.0000 |
| 77 |
DEATH |
4 |
0.0000 |
| 78 |
OVERDOSE |
1 |
0.0000 |
| 79 |
BACK PAIN |
1 |
0.0000 |
| 80 |
PRODUCT USE IN UNAPPROVED INDICATION |
1 |
0.0000 |
| 81 |
DRUG INEFFECTIVE |
5 |
0.0000 |
| 82 |
INSOMNIA |
1 |
0.0000 |
| 83 |
PRODUCT DOSE OMISSION ISSUE |
1 |
0.0000 |
| 84 |
CONDITION AGGRAVATED |
1 |
0.0000 |
| 85 |
DIARRHOEA |
2 |
0.0000 |
| 86 |
PNEUMONIA |
1 |
0.0000 |
| 87 |
PYREXIA |
1 |
0.0000 |
| 88 |
VOMITING |
1 |
0.0000 |
| 89 |
DIZZINESS |
1 |
0.0000 |
| 90 |
NAUSEA |
1 |
0.0000 |